HOME > 教室紹介 > 研究業績 > 英文総説

教室紹介

教室紹介

研究業績

英文総説

2017年 2016年 2015年
2014年 2013年 2012年
2011年 2010年 2009年
2008年 2007年 2006年
2005年    

2017年
  1. Ventura-Clapier R, Dworatzek E, Seeland U, Kararigas G, Arnal JF Brunelleschi S, Carpenter T, Erdmann J, Franconi F, Giannetta E, Glezerman M, Hofmann S, Junien C, Katai M, Kublickiene K, Konig IR, Majdic G, Malorni W, Mieth C, Miller V, Reynolds R, Shimokawa H, Tannenbaum C, D`Ursi AM, Regitz-Zagrosek V. Sex in basic research -Concepts in the cardiovascular field- Cardiovasc Res. (in press)
  2. Aoki T, Shimokawa H. Earthquake and hypertension. -From acute to chronic phase after the Great East Japan Earthquake- (Commentary) Xiangya Medicine. (in press)
  3. Godo S, Shimokawa H. Divergent roles of endothelial nitric oxide synthases system in maintaining cardiovascular homeostasis. Free Radical Biology & Medicine. DOI:10.1016/j.freeradbiomed.2016.12.019PDF
  4. Crea F, Merz CNB, Beltrame JF, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Camici P: COVADIS Group. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 38:473-477,2017.PDF
  5. Ohyama K, Matsumoto Y, Shimokawa H. Impact of epicardial adipose tissue volume quantified by non-contrast electrocardiogram-gated computed tomography on ergonovine-induced epicardial coronary artery spasm. (Letter to the Editor) Int J Cardiol. 229:40,2017.PDF
  6. Beltrame J, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Merz CNB; COVADIS Group. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. doi:10.1093/eurheartj/ehv351.PDF
2016年
  1. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Merz CNB, the COVADIS Group. The who, what, why, when, how and where of vasospastic angina. Circ J. 80:289-298,2016.PDF
  2. JCS, JSH and JCC Joint Working Group (Shimokawa H, Kario K, Daida H, et al.) Guidelines for disaster medicine for patients with cardiovascular disease (JCS 2014/JSH 2014/JCC 2014). Circ J. 80:261-284,2016. PDF
  3. Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. (Editorial) ESC Heart Failure. 3:145-151,2016. PDF
  4. Merz CN, Beltrame J, Camici P, Crea F, Kaski JC, Ogawa H, Peter P, Sechtem U, Shimokawa H. A shocking development in a young male athlete with chest pain (Letter to the Editor). Circulation. 133:756-763,2016.PDF
  5. Shimokawa H. The 8-year journey with the Circulation Journal. (Editorial) Circ J. 80:1661-1664,2016. PDF
  6. Shimokawa H, Godo S. Diverse functions of endothelial NO synthases system: NO and EDH. J Cardiovasc Pharmacol. 67:361-366,2016.PDF
  7. Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res. 118:352-366,2016.PDF
  8. Sugimura K, Satake H, Shimokawa H. Respiratory therapy in chronic heart failure patients complicated with sleep-disordered breathing: potential study bias. (Authors’ reply) Circ J. 80:1486-1487,2016.PDF
  9. Sugimura K, Shimokawa H. Ischemic lesion formation in solitary tract nuclei during central sleep apnea with heart failure -Authors’ reply- Circ J. 80:1049,2016.PDF
  10. Takahashi J, Satoh K, Fukuda K, Sugimura K, Matsumoto Y, Nakano M, Tsuburaya R, Aoki T, Hao K, Nishimiya K, Ito K, Sakata Y, Shimokawa H. Overview of the 80th annual scientific meeting of the Japaanese Circulation Society. -The Past, Present and Future Cardiovascular Medicine in Japan- -The 5th anniversary of the Great East Japan Earthquake- Circ J. 80:1689-1694,2016.PDF
  11. Yaoita N, Satoh K, Shimokawa H. Novel therapeutic targets of pulmonary hypertension. (Review) Arteriosclr Thromb Vasc Biol. 2016;36:e97-e102. DOI: 10.1161/ATVBAHA.116.308263.PDF

研究業績一覧へ |このページのTOPへ

2015年
  1. Ito K, Shimokawa H. The future of non-invasive angiogenic therapy using acoustic waves. Circ J. 79:1906-1907,2015. PDF
  2. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail. 17:884-892,2015PDF
  3. Shimokawa H, Satoh K. 2015 ATVB Plenary lecture: Translational research on Rho-kinase in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 35:1756-1769,2015.PDF
  4. Shimokawa H, Satoh K. Light and dark of reactive oxygen species for vascular function. J Cardiovasc Pharmacol. 65:412-418,2015.PubMed
  5. Satoh K, Kikuchi N, Kurosawa R, Shimokawa H. PDE1C negatively regulates growth factor receptor degradation and promotes VSMC proliferation. Circ Res. 116:1098-1100,2015.PDF
  6. Satoh K. Cyclophilin A in cardiovascular homeostasis and diseases. Tohoku J Exp Med. 235:1-15,2015.PDF
  7. Tsutsui M, Tanimoto A, Tamura M, Mukae H, Yanagihara N, Shimokawa H, Otsuji Y. Significance of nitric oxide synthases: Lessons from triple nitric oxide synthases null mice. J Pharmacol Sci. 127:42-52,2015.PDF

研究業績一覧へ |このページのTOPへ

2014年
  1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 1:4-25,2014.
  2. Satoh K, Godo S, Saito H, Enkhjargal S, Shimokawa H. Dual roles of vascular-derived reactive oxygen species -With a special reference to hydrogen peroxide and cyclophilin A- J Mol Cell Cardiol. 73:50-56,2014.PDF
  3. Satoh K, Shimokawa H. High-sensitivity C-reactive protein: Still need for next-generation biomarkers for remote future cardiovascular events. Eur Heart J. 35:1776-1778,2014. (Editorial)PDF
  4. Shimokawa H. 2014 William Harvey Lecture. Importance of coronary vasomotion abnormalities -From bench to bedside- Eur Heart J. 35:3180-3193,2014.PDF
  5. Shimokawa H, Ogawa H. Prognostic stratefication of patients with vasospastic angina. J Am Coll Cardiol. 63:1585-1586,2014.PDF
  6. Shimokawa H, Satoh K. Recent Highlights of ATVB: Vascular function. Arteriosclr Thromb Vasc Biol. 34:2359-2362,2014.
  7. Suzuki H, Matsumoto Y, Shimokawa H. Cerebral blood flow in Takotsubo syndrome: Is it specific for the disease? -Reply- Circ J. 78:776,2014.PubMed
  8. Tsutsui M, Shimokawa H, Tanimoto A, Yanagihara N, Otsuji Y. Roles of nitric oxide synthases in arteriosclerotic vascular disease-Insights from murine genetic models- J Clin Exp Cardiol. 5: 318. doi:10.4172/2155-9880.1000318,2014.PDF

研究業績一覧へ |このページのTOPへ

2013年
  1. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 77:2209-2217,2013.PDF
  2. Sakata Y, Shimokawa H. Saturated fatty acid intake and cardiovascular risk. Eur Heart J. 34:1178-1180,2013.PDF
  3. Shibata K, Shimokawa H, Yanagisawa N, Otsuji Y, Tsutsui M. Nitric oxide synthases and heart failure -Lessons from genetically manipulated mice- J UOEH. 35:147-158,2013.PDF
  4. Shimokawa H. Reactive oxygen species promote vascular smooth muscle cell proliferation. Circ Res. 113:1040-1042,2013.PDF

研究業績一覧へ |このページのTOPへ

2012年
  1. Kagaya Y, Asaumi Y, Wang W, Takeda M, Nakano M, Satoh K, Fukumoto Y, Shimokawa H. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target. Tohoku J Exp Med. 227:83-91,2012.PDF
  2. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 33:436-443,2012.PDF
  3. Satoh K, Fukumoto Y, Nakano M, Kagaya Y, Shimokawa H. Emergence of the erythropoietin/erythropoietin receptor system as a novel cardiovascular therapeutic target. J Cardiovasc Pharmacol. 58:570-574,2012.PubMed
  4. Shiba N, Shimokawa H. Prospective care of heart failure in Japan: Lessons from CHART Studies. EPMA. 2:425-438,2012.PDF

研究業績一覧へ |このページのTOPへ

2011年
  1. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J. 75:1801-1810,2011. PDF
  2. Ito K, Fukumoto Y, Shimokawa H. Extracorporeal shock wave therapy for ischemic cardiovascular disorders. Am J Cardiovasc Drugs. 11:295-302,2011.PubMed
  3. Satoh K, Berk BC, Shimokawa H. Vascular-derived reactive oxygen species for homeostasis and diseases. Nitric Oxide. 25:211-215,2011. PDF
  4. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol. 301:287-296,2011.PDF
  5. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol. 57:8-17,2011. PDF

研究業績一覧へ |このページのTOPへ

2010年
  1. Ito K, Kagaya Y, Shimokawa H. Thyroid hormone and chronically unloaded hearts. Vasc Pharmacol. 52:138-141,2010.PDF
  2. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch Eur J Physiol. 459:915-922,2010.PDF
  3. Shimokawa H, Tustsui M. Nitric oxide synthases in the pathogenesis of cardiovascular disease. Pflugers Arch Eur J Physiol. 459:959-967,2010.PDF
  4. Tsutsui M, Shimokawa H, Otsuji Y, Yanagihara N. Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacology & Therapeutics. 128:499-508,2010.PDF

研究業績一覧へ |このページのTOPへ

2009年
  1. Ito K, Fukumoto Y, Shimokawa H. Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. Tohoku J Exp Med. 219:1-9,2009.PDF
  2. Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic target. Circ J. 73:394-403,2009.PDF
  3. Tsutsui M, Shimokawa H, Otsuji Y, Ueta Y, Sasaguri Y, Yanagihara N. Nitric oxide synthases and cardiovascular diseases-Insights from genetically modified mice-. Circ J. 73:986-993,2009.PDF
  4. Vanhoutte PM, Shimokawa H, Tang EHC, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol. 196:193-222,2009.PDF
  5. Yasuda S, Shimokawa H. Acute myocardial infarction-The enduring challenge for cardiac protection and survival-. Circ J. 73:2000-2008,2009.PDF

研究業績一覧へ |このページのTOPへ

2008年
  1. Shiba N, Shimokawa H. Chronic heart failure in Japan: Implications of the CHART studies. Vascular Health and Risk Management. 4:103-113,2008.PDF
  2. Shimokawa H, Ito K, Fukumoto Y, Yasuda S. Extracorporeal cardiac shock wave therapy for ischemic heart disease. Shock Wave. 17:449-455,2008.
  3. Shimokawa H, Yasuda S. Myocardial ischemia: current concepts and future perspectives. J Cardiol. 52:67-78,2008.PDF
  4. Tsutsui M, Nakata S, Shimokawa H, Otsuji Y, Yanagihara N. Spontaneous myocardial infarction and nitric oxide synthase. JTrend Cardiovasc Sci. 18:275-279,2008.PDF

研究業績一覧へ |このページのTOPへ

2007年
  1. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension -Expectation for Rho-kinase inhibitors-. Tohoku J Exp Med. 211:309-320,2007.PDF
  2. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 28:296-302,2007.PDF

研究業績一覧へ |このページのTOPへ

2006年
  1. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y, Yanagihara N. Development of genetically engineered mice lacking all three nitric oxide synthases. J Pharmacol Sci. 102:147-154,2006.PDF

研究業績一覧へ |このページのTOPへ

2005年
  1. Hirooka Y, Shimokawa H. Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs. 5:31-39,2005.PubMed
  2. Komaru T, Shirato K. Myocardial ischemia and coronary microvascular vasomotion: The impact of hypercholesterolemia. Future Cardiol. 1:637-647,2005.PubMed
  3. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 25:1767-1775,2005.PDF
  4. Shimokawa H, Morikawa K. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. J Mol Cell Cardiol. 39:725-732,2005.PDF

研究業績一覧へ |このページのTOPへ